Szemészet, 1975 (112. évfolyam, 1-3. szám)

1975 / 3. szám

We may conclude that 10% glycerol + 10% sodium ascorbate, administered intravenously at a rate of 100 drops per minute and at doses of 0.6—1 g/Kg body weight, present the following advantages:

— absence of hemoglobinuria and hematuria (which on the contrary were observed following intravenous 10% glycerol in saline);

— clinical use as an osmotic agent to markedly reduce the intraocular pres— sure; stability of the preparation (about two years duration);

— absence of significant changes in blood sugar levels both in normal and in diabetic patients.

Summary

In consideration of the occurrence of microscopic and, in some cases, macroscopic hematuria both in the experimental animal and in man, following the intravenous infusion of 10% glycerol in saline, the Authors advise against its clinical use.

The use of intravenous glycerol is possible, according to the researches of the Authors, only in association with sodium ascorbate.

This work proposes the clinical use of 10% glycerol + 10% sodium ascorbate, at the rate of 100 drops per minute and the doses of 0.8—1 g/Kg body weight, which presents the following advantages:

— absence of hemoglobinuria and hematuria;

— clinical use as an osmotic agent to reduce the intraocular pressure;

— stability of preparation (about two years duration);

— absence of significant changes in blood sugar levels both in normal and diabetic patients.

REFERENCES: 1. Bővet, D.—Cantore, G.—Guidetti, B. and M. Virno: Gazz. Int. Med. Chir. 65, 3021, 1961. — 2. Cantore, G. P.—Guidetti, B. and M. Virno: J. Neurosui'g. 21, 278, 1964. — 3. Cantore, G. P.—Guidetti, B.—Pecori-Giraldi, J. and M. Virno: II Policlinico (Sez. pratica) 73, 553, 1966. — 4. Della Восса, L.—Pecori-Giraldi, J.— Cantore, G. P. and M. Virno: Gazz. Int. Med. Chir. 70, 944, 1966. — 5. El-Shewi, T. M. and M. E. El-Sayed: Ophthalmologica 168, 39, 1974. — 6. Hagnevik, K.—Gordon, Lins, L. E. and S. Wilhelmsson: Lancet I, 75, 1974. — 7. Hilsdorf, C.: Klin. МЫ. Augenheilk. 150, 352, 1967. — 8. Holtman, H. W.: Klin. МЫ. Augenheilk. 161, 322,

1973. — 8. Ikeda, I.—Sakamoto, Y.—Tanabe, Y.—Imaizumi, M. and B. Azuma: Jap. J. Clin. Ophthal. 22, 349, 1968. — 9. Lebkowski, J. et al.: Pol. Tyg. Lek. 25, 1808, 1970. — 10. Mathew, N. T.—Meyer, J. S.—Bivera, V. M.—Charney, J. Z. and A. Hartmann: Lancet II, 7791, 1972. — 11. Meyer, J. S.—Charney, J. Z.—Bivera, V. M. and Mathew, N. T.: Lancet II, 7732, 1971. — 12. Beddy, P. S.—Satapathy, M. and Beddy, P. B.: Orient. Arch. Ophthal. 7, 291, 1969. — 13. Beinglas, J. L.: Neurology (Minneapolis) 24, 743, 1974. — 14. Suzuki, Y.—Okada, N. and Saeki, N.: Folia Ophthal. Jap. 17, 478, 1966. — 15. Suzuki, Y.—Kitazawa, Y. and K. Kawanishi: Acta Soc. Ophthal. Jap. 71, 481, 1967. — 16. Tams, G.: Klin. Mbl. f. Augenheilk. 158, 663, 1971. — 17. Tsun-Mou, S. and Y. Ming-Ching: Chinese Med. J. 1, 64, 1975. — 18. Tourtellotte, W. W.—Beinglass, J. L. and T. L. Newkirk: Clin. Pharmacol. Therap. 13, 159, 1972. —- 19. Virno, M.—Chiavarelli, S. and G. P. Cantore: Gazz. Int. Chir. Med. 66, 3509, 1961. — 20. Virno, M.—Cantore, в. P.—Bietti, C. and M. G. Bucci: Amer. J. Ophthal. 55, 1133, 1963. — 21. Virno, M.—Pecori-Giraldi, J.—Cantore, G. P. and V. Gagli: II Policlinico (Se. Pratica) 72, 1746, 1965. — 22. Virno, M.—Bucci, M. G.— Pecori- Giraldi, J. and G. P. Cantore: Boli. Ocul. 44, 225, 1965. — 23. Virno, M~.—Delia Восса, L.—Pecori-Giraldi, J. and G. P. Cantore: Gazz. Int. Med. Chir. 70, 1160, 1966. — 24. Virno, M.—Bucci, M. G.—Pecori-Giraldi, J. and G. P. Cantore: Amer. J. Ophthal. 62, 824, 1966. — 25. Virno, M.—Molteni, L.—Scollini, M.—Pecori-Giraldi, J. and E. D. Motelese: Boli. Ocul. 1975. (in press). — 26. Welch, K. M. Letter: Lancet I, 416,

1974.

173